A share price of Silence Therapeutics Plc ADR [SLN] is currently trading at $22.36, up 5.72%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SLN shares have gain 4.39% over the last week, with a monthly amount drifted -13.67%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 8, April 2024, Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a). In a post published today on Yahoo Finance, Published findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp(a) after single and multiple dosing.
From an analyst’s perspective:
Silence Therapeutics Plc ADR [NASDAQ: SLN] stock has seen the most recent analyst activity on January 31, 2024, when BMO Capital Markets initiated its Outperform rating and assigned the stock a price target of $67.
Silence Therapeutics Plc ADR experienced fluctuations in its stock price throughout the past year between $4.55 and $27.72. Currently, Wall Street analysts expect the stock to reach $38 within the next 12 months. Silence Therapeutics Plc ADR [NASDAQ: SLN] shares were valued at $22.36 at the most recent close of the market. An investor can expect a potential return of 69.95% based on the average SLN price forecast.
Analyzing the SLN fundamentals
Trailing Twelve Months sales for Silence Therapeutics Plc ADR [NASDAQ:SLN] were 31.36M which represents -53.41% decline. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -1.95%, Pretax Profit Margin comes in at -1.98%, and Net Profit Margin reading is -1.71%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -2.63 and Total Capital is -0.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.32 points at the first support level, and at 20.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.98, and for the 2nd resistance point, it is at 23.59.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Silence Therapeutics Plc ADR [NASDAQ:SLN] is 4.56. As well, the Quick Ratio is 4.56, while the Cash Ratio is 3.04. Considering the valuation of this stock, the price to sales ratio is 28.25, the price to book ratio is 40.75.
